Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors.
Fiche publication
Date publication
mars 2022
Journal
The oncologist
Auteurs
Membres identifiés du Cancéropôle Est :
Pr CHENARD Marie-Pierre, Dr DAVIDSON Irwin, Pr KURTZ Jean-Emmanuel, Dr LINDNER Véronique, Pr MALOUF Gabriel, Pr MASCAUX Céline, Dr GANTZER Justine
Tous les auteurs :
Gantzer J, Davidson G, Vokshi B, Weingertner N, Bougoüin A, Moreira M, Lindner V, Lacroix G, Mascaux C, Chenard MP, Bertucci F, Davidson I, Kurtz JE, Sautès-Fridman C, Fridman WH, Malouf GG
Lien Pubmed
Résumé
Thoracic SMARCA4-deficient undifferentiated tumors (SMARCA4-UT) are aggressive neoplasms. Data linking BAF alterations with tumor microenvironment (TME) and efficacy of immune checkpoint inhibitors (ICI) are contradictory. The TME of SMARCA4-UT and their response to ICI are unknown.
Mots clés
SMARCA4-deficiency, immune infiltrate, immunotherapy, sarcomas, thoracic tumors, tumor microenvironment
Référence
Oncologist. 2022 Mar 12;: